Results for: Primary Biliary Cholangitis

Tharimmune, Inc. (THAR) stock skyrocketed on Wednesday after the company received positive feedback from the European Medicines Agency (EMA) regarding its TH104 clinical program for treating pruritus in primary biliary cholangitis. This positive news, combined with the company’s commitment to advancing innovative solutions in inflammation and immunology, has investors excited about the future of TH104.

The FDA has granted accelerated approval to Gilead Sciences’ Livdelzi (seladelpar) for the treatment of primary biliary cholangitis (PBC) in adults. Livdelzi can be used in combination with ursodeoxycholic acid (UDCA) for those who haven’t responded well to UDCA or as monotherapy for patients unable to tolerate UDCA.